Despite April 2014's Issue Of 'Journal Of The American College Of Cardiology,' NeoStem's AMR-001 Maintains Its Leverage For Stem Cell Based MI Treatment
- The benefits of including CD34+ cells in AMR-001.
- The benefits of including CXCR4+ cells in AMR-001.
- A new study indicates equal efficacy of autologous and allogeneic cell therapy for CAD.
- If you are not long in NBS, a good time to buy will be after April 8, 2014; release date of April's issue of JACC.